Home › Trial NCT07604233
Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
- Trial IDNCT07604233
- StatusNot Yet Recruiting
- PhasePhase 1/2
- Study typeInterventional
- SponsorM.D. Anderson Cancer Center
- Enrollment30
- Start date2026-11-30
- ConditionsMyeloid Leukemia
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.